These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 3276562

  • 1. Secretory dynamics of bioactive and immunoreactive prolactin in polycystic ovary syndrome.
    Anderson RE, Ben-Rafael Z, Flickinger GL, Meloni F, Barnes RB, Rosen GF, Lobo RA.
    Fertil Steril; 1988 Feb; 49(2):239-43. PubMed ID: 3276562
    [Abstract] [Full Text] [Related]

  • 2. Metoclopramide effect on serum prolactin LH and FSH in patients with polycystic ovary syndrome.
    Prelević GM, Würzburger MI, Perić LA.
    J Endocrinol Invest; 1988 Apr; 11(4):255-9. PubMed ID: 3137253
    [Abstract] [Full Text] [Related]

  • 3. Effects of dopamine and metoclopramide in polycystic ovary syndrome.
    Barnes RB, Mileikowsky GN, Cha KY, Spencer CA, Lobo RA.
    J Clin Endocrinol Metab; 1986 Aug; 63(2):506-9. PubMed ID: 3722335
    [Abstract] [Full Text] [Related]

  • 4. Hypothalamic dopaminergic tone and prolactin bioactivity in women with polycystic ovary syndrome.
    Hernández I, Parra A, Méndez I, Cabrera V, Cravioto MC, Mercado M, Díaz-Sánchez V, Larrea F.
    Arch Med Res; 2000 Aug; 31(2):216-22. PubMed ID: 10880731
    [Abstract] [Full Text] [Related]

  • 5. Prolactin response after gonadotropin-releasing hormone in the polycystic ovary syndrome.
    Shoupe D, Lobo RA.
    Fertil Steril; 1985 Apr; 43(4):549-53. PubMed ID: 3921411
    [Abstract] [Full Text] [Related]

  • 6. Further evidence against dopamine deficiency as the cause of inappropriate gonadotropin secretion in patients with polycystic ovary syndrome.
    Rosen GF, Lobo RA.
    J Clin Endocrinol Metab; 1987 Nov; 65(5):891-5. PubMed ID: 3117832
    [Abstract] [Full Text] [Related]

  • 7. Prolactin release in polycystic ovarian syndrome.
    Minakami H, Abe N, Oka N, Kimura K, Tamura T, Tamada T.
    Endocrinol Jpn; 1988 Apr; 35(2):303-10. PubMed ID: 3145187
    [Abstract] [Full Text] [Related]

  • 8. Metoclopramide test in women with PCO syndrome after ovarian wedge resection.
    Vĕtr M, Talas M, Sobek A, Charamza J.
    Acta Univ Palacki Olomuc Fac Med; 1991 Apr; 130():257-64. PubMed ID: 1838876
    [Abstract] [Full Text] [Related]

  • 9. Neuroendocrine dopaminergic regulation of prolactin release in systemic lupus erythematosus: a possible role of lymphocyte-derived prolactin.
    Méndez I, Alcocer-Varela J, Parra A, Lava-Zavala A, de la Cruz DA, Alarcón-Segovia D, Larrea F.
    Lupus; 2004 Apr; 13(1):45-53. PubMed ID: 14870917
    [Abstract] [Full Text] [Related]

  • 10. Effect of luteal metoclopramide-induced hyperprolactinemia on pituitary and luteal responsiveness to gonadotropin-releasing hormone.
    Caruso A, Lanzone A, Fulghesu AM, Apa R, Guida C, Mancuso S.
    Horm Res; 1989 Apr; 31(4):169-74. PubMed ID: 2507435
    [Abstract] [Full Text] [Related]

  • 11. Decreased dopaminergic tone and increased basal bioactive prolactin in men with human immunodeficiency virus infection.
    Parra A, Ramírez-Peredo J, Larrea F, Cabrera V, Coutiño B, Torres I, Angeles A, Pérez-Romano B, Ruiz-Argüelles G, Ruiz-Argüelles A.
    Clin Endocrinol (Oxf); 2001 Jun; 54(6):731-8. PubMed ID: 11422107
    [Abstract] [Full Text] [Related]

  • 12. Hyperprolactinemia in polycystic ovary syndrome.
    Luciano AA, Chapler FK, Sherman BM.
    Fertil Steril; 1984 May; 41(5):719-25. PubMed ID: 6425087
    [Abstract] [Full Text] [Related]

  • 13. The control of bioactive luteinizing hormone secretion in women with polycystic ovary syndrome.
    Lobo RA, Shoupe D, Chang SP, Campeau J.
    Am J Obstet Gynecol; 1984 Feb 15; 148(4):423-8. PubMed ID: 6364811
    [Abstract] [Full Text] [Related]

  • 14. Prolactin levels in the polycystic ovary syndrome.
    Milewicz A.
    J Reprod Med; 1984 Mar 15; 29(3):193-6. PubMed ID: 6233421
    [Abstract] [Full Text] [Related]

  • 15. The effect of bromocriptine on gonadotropin and steroid secretion in polycystic ovarian disease.
    Steingold KA, Lobo RA, Judd HL, Lu JK, Chang RJ.
    J Clin Endocrinol Metab; 1986 May 15; 62(5):1048-51. PubMed ID: 2937800
    [Abstract] [Full Text] [Related]

  • 16. The hyperprolactinemic polycystic ovary syndrome may not be an distinct entity.
    Corenblum B, Taylor PJ.
    Fertil Steril; 1982 Nov 15; 38(5):549-52. PubMed ID: 6813147
    [Abstract] [Full Text] [Related]

  • 17. Paradoxical growth hormone response following thyroid-stimulating hormone administration in the polycystic ovary syndrome.
    Anapliotou ML, Syrigos K, Panayiotakopoulos G, Kalos A, Batrinos ML.
    Horm Res; 1989 Nov 15; 31(3):119-24. PubMed ID: 2501207
    [Abstract] [Full Text] [Related]

  • 18. Prolactin release in polycystic ovary.
    Falaschi P, del Pozo E, Rocco A, Toscano V, Petrangeli E, Pompei P, Frajese G.
    Obstet Gynecol; 1980 May 15; 55(5):579-82. PubMed ID: 6768043
    [Abstract] [Full Text] [Related]

  • 19. Evidence that an altered prolactin release is consequent to abnormal ovarian activity in polycystic ovary syndrome.
    Paoletti AM, Cagnacci A, Soldani R, Orrù M, Ajossa S, Pittorra G, Mulas P, Melis GB.
    Fertil Steril; 1995 Dec 15; 64(6):1094-8. PubMed ID: 7589658
    [Abstract] [Full Text] [Related]

  • 20. Gonadotropin responses to gonadotropin-releasing hormone and prolactin responses to thyrotropin-releasing hormone and metoclopramide in women with amenorrhea and insulin-treated diabetes mellitus.
    Djursing H, Hagen C, Nyholm HC, Carstensen L, Andersen AN.
    J Clin Endocrinol Metab; 1983 May 15; 56(5):1016-21. PubMed ID: 6403566
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.